Discussion
An accelerated review will be given an application for European Union approval of ciltacabtagene autoleucel (cilta-cel), a potential CAR T-cell therapy for heavily pre-treated multiple myeloma patients,…
Myeloma
Myeloma is a rare blood cancer that begins in plasma cells, a type of white blood cell normally responsible for producing antibodies that help fight off infectious pathogens and other threats.
While myeloma treatment can drive the disease into remission, sometimes for long periods of time, the cancer will often come back after a few months or years, and additional treatments will be needed.
Latest news
Discussion
Discussion
A combination of Nexpovio (selinexor) and the corticosteroid dexamethasone has been recommended for conditional approval in the European Union to treat adults with relapsed…
Discussion
Cerecor has dosed the first patient in a Phase 1b clinical trial evaluating  CERC-007 as a potential treatment for relapsed or refractory multiple…
Discussion
Combining the corticosteroid methylprednisolone and Jakafi (ruxolitinib), an approved oral therapy for bone marrow disorders, is showing promising effectiveness in heavily pre-treated multiple myeloma…
Discussion
A new research center at Ohio State University (OSU) aims to speed work into the discovery and development of more effective treatments for those with…
Discussion
The first patient has been dosed in Celyad Oncology’s Phase 1 clinical trial evaluating CYAD-211, an investigational donor-derived CAR T-cell therapy for treating relapsed…
